Today: 17 April 2026
Subscribe
Browse Category

NASDAQ:SPRE 4 January 2026 - 23 February 2026

Spyre Therapeutics stock dips premarket after Friday surge as $500 million shelf hangs over shares

Spyre Therapeutics stock dips premarket after Friday surge as $500 million shelf hangs over shares

Spyre Therapeutics shares dropped 4.2% to $41.38 in premarket trading Monday after a 14.3% surge Friday. The move follows Thursday’s filing of a $500 million shelf registration, raising dilution concerns. Investors are watching for initial Phase 2 ulcerative colitis data, expected in the second quarter of 2026. Spyre ended 2025 with $757 million in cash and marketable securities.
23 February 2026
·
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Spyre Therapeutics shares dropped 6.6% to $30.58 on Friday, closing near session lows after about 889,000 shares traded. The move followed comments from Philadelphia Fed President Anna Paulson signaling rate cuts may be delayed. Spyre remains below its 52-week high of $34.49, with traders eyeing whether the stock can hold above $30 at Monday’s open. No significant company news has been released since the last quarterly update.
4 January 2026
·

Stock Market Today

  • Symbotic (SYM) Valuation Shows Mixed Signals Amid Strong Backlog and Cash Flow Models
    April 17, 2026, 4:47 AM EDT. Symbotic (SYM) shares hover near $60.56 after a strong 197% total return over the past year and 19.9% revenue growth. The company boasts a record $22.4 billion backlog, reflecting robust demand for its warehouse automation systems amid rising e-commerce adoption. Analysts' valuation models diverge: a narrative-based fair value of $64.05 suggests the stock is 5.4% undervalued, relying on rapid backlog conversion and margin expansion. In contrast, a discounted cash flow (DCF) model values shares at $47.64, signaling overvaluation based on cash flow projections. This valuation split highlights uncertain assumptions about Symbotic's ability to translate its backlog into sustainable cash earnings, with risks including customer concentration and contract delays.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 17.04.2026

17 April 2026
LIVEMarkets rolling coverageStarted: April 17, 2026, 12:00 AM EDTUpdated: April 17, 2026, 4:47 AM EDT Symbotic (SYM) Valuation Shows Mixed Signals Amid Strong Backlog and Cash Flow Models April 17, 2026, 4:47 AM EDT. Symbotic (SYM) shares hover near $60.56 after a strong 197% total return over the past year and 19.9% revenue growth. The company boasts a record $22.4 billion backlog, reflecting robust demand for its warehouse automation systems amid rising e-commerce adoption. Analysts' valuation models diverge: a narrative-based fair value of $64.05 suggests the stock is 5.4% undervalued, relying on rapid backlog conversion and margin expansion. In contrast,
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

16 April 2026
Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
NuScale Power Stock Whipsaws After U.S. Opens Door to Nuclear Loans, Space Reactor Push

NuScale Power Stock Whipsaws After U.S. Opens Door to Nuclear Loans, Space Reactor Push

16 April 2026
NuScale Power shares jumped to $13.23 before falling back to $11.52 Thursday after the White House ordered NASA to start a space-reactor program and Energy Secretary Chris Wright said initial U.S. reactors would likely get federal loans. NuScale remains the only U.S. firm with an approved small modular reactor design but has yet to secure firm orders or financing.
SoFi Technologies Stock Rises as FedNow Instant Transfers Set Up April 29 Earnings Test

SoFi Technologies Stock Rises as FedNow Instant Transfers Set Up April 29 Earnings Test

16 April 2026
SoFi Technologies shares rose 1.5% Thursday after launching instant bank transfers via its Galileo platform, allowing money to move between SoFi and outside banks in seconds. The stock traded near $19.08 in New York. Investors await first-quarter results April 29, with SoFi guiding to $1.04 billion in adjusted net revenue and 12 cents per share in adjusted earnings.
D-Wave Quantum Stock Jumps Again as Nvidia’s Ising Launch Reignites Quantum Rally

D-Wave Quantum Stock Jumps Again as Nvidia’s Ising Launch Reignites Quantum Rally

16 April 2026
D-Wave Quantum shares climbed about 5% Thursday, extending a 22.6% surge after Nvidia launched Ising, a new AI model family for quantum computing. D-Wave traded at $21.81, up from last year’s lows, and reported 2025 revenue of $24.6 million with first-quarter 2026 bookings topping $32.8 million. The company completed its $250 million Quantum Circuits acquisition in January. Market cap stood near $8.4 billion.
Go toTop